A patient may celebrate losing 20 kilograms while unknowingly sacrificing a substantial amount of the very tissue that protects metabolic health, maintains functional capacity, and supports healthy aging. Smaller clothing sizes do not necessarily indicate a healthier body composition. A lower number on the scale does not automatically mean a better metabolic outcome.
The physiological explanation is straightforward. These medications reduce appetite and food intake, often dramatically. While this reduction in calorie consumption drives fat loss, it can also reduce protein intake. When dietary protein becomes insufficient, the body may obtain amino acids from existing muscle tissue to meet its biological needs. At the same time, many individuals become less physically active or fail to engage in resistance training, removing the mechanical stimulus required to preserve muscle mass.
From an evolutionary perspective, muscle is metabolically expensive tissue. During periods of perceived energy scarcity, the body often adapts by reducing both fat stores and lean tissue unless there is a compelling reason to maintain muscle. Adequate protein intake and resistance exercise provide that reason.
This is why successful obesity treatment should not focus exclusively on weight loss. The goal should be fat loss while preserving lean mass. These are not the same thing.
Patients receiving GLP-1 receptor agonists or dual agonists should be encouraged to prioritize dietary protein, engage in regular resistance training, and monitor body composition whenever possible. Measurements such as DXA scans, bioimpedance analysis, waist circumference, strength assessments, and functional performance tests provide a far more meaningful picture of health than body weight alone.
The future of obesity medicine should move beyond the simplistic concept of weight reduction. Excess body fat contributes to metabolic disease, but skeletal muscle is one of the body’s greatest protective organs. The ideal outcome is not maximum weight loss. The ideal outcome is maximum fat loss with minimum muscle loss.
As clinicians, we must remember that our patients do not simply need to become lighter. They need to become metabolically healthier, physically stronger, and more resilient.
The scale measures weight.
Body composition measures health.
And when it comes to long-term metabolic health, strength, function, and longevity, muscle may be the most important tissue we possess.
References
1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002.
2. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Placebo on Body Composition in Adults with Overweight or Obesity. STEP 1 DXA Substudy.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216.
4. SURMOUNT-1 Body Composition Substudy Investigators. Effects of Tirzepatide on Fat Mass and Lean Mass Distribution in Adults with Obesity.
5. Systematic Review of Muscle-Related Outcomes Associated with Incretin-Based Therapies. Annals of Internal Medicine. 2026.
6. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: Revised European Consensus on Definition and Diagnosis. Age and Ageing. 2019;48(1):16-31.
7. Wolfe RR. The Underappreciated Role of Muscle in Health and Disease. American Journal of Clinical Nutrition. 2006;84(3):475-482.
8. Srikanthan P, Karlamangla AS. Muscle Mass Index as a Predictor of Longevity in Older Adults. American Journal of Medicine. 2014;127(6):547-553
Dr. Berry Dubiso, MD
Dr Berry Right Medical Consultancy Contact & Location
📞 0911581692
DrBerry Health Consultancy
Gerji (Totot), Addis Ababa
Right Medical Consultancy
Bole, DH Geda Tower, Addis Ababa
Service registration link:
https://form.drberrydubiso.com
Facebook:
https://www.facebook.com/share/15ku8YYkV8X/?mibextid=wwXIfr
Telegram:
https://t.me/drberrydubiso